Abstract
The advent of protein kinase inhibitors and immunotherapy has profoundly improved the management of advanced melanoma. However, with these therapeutic advancements also come drug-related toxicities that have the potential to affect various organ systems. We review dermatologic adverse events from targeted (including BRAF and MEK inhibitor-related) and less commonly used melanoma treatments, with a focus on diagnosis and management. As immunotherapy-related toxicities have been extensively reviewed, herein, we discuss injectable talimogene laherparepvec and touch on recent breakthroughs in the immunotherapy space. Dermatologic adverse events may severely impact quality of life and are associated with response and survival. It is therefore essential that clinicians are aware of their diverse presentations and management strategies.
Original language | English (US) |
---|---|
Pages (from-to) | 765-785 |
Number of pages | 21 |
Journal | American Journal of Clinical Dermatology |
Volume | 24 |
Issue number | 5 |
DOIs | |
State | Published - Sep 2023 |
ASJC Scopus subject areas
- Dermatology